SLC5A2 and type 2 diabetes mellitus: In the last decade, we have learnt of the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in people with type 2 diabetes (T2D).